Pluristem's successful stem cell trial last week on muscle injuries is an important first step for the company, says the company's CEO Zami Aberman. By using placental cells, Pluristem eliminates the ethical issues surrounding where the cells are derived, according to Aberman, who also touts his company's unique ability to manufacture 3D cells. Aberman is also bullish on Pluristem's partnership with United Therapeutics, another biotech company that has seen its shares spike in the past year.
More from Video
How quickly do we find support, is what we'll want to know now, as the correction is occurring while economic optimism builds.
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.